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Abstract
UDP-GlcNAc:lysosomal enzyme N-acetylglucosamine-1-phosphotransferase is an a2b2c2 hexameric enzyme that catalyzes
the synthesis of the mannose 6-phosphate targeting signal on lysosomal hydrolases. Mutations in the a/b subunit precursor
gene cause the severe lysosomal storage disorder mucolipidosis II (ML II) or the more moderate mucolipidosis III alpha/beta
(ML III a/b), while mutations in the c subunit gene cause the mildest disorder, mucolipidosis III gamma (ML III c). Here we
report neurologic consequences of mouse models of ML II and ML III c. The ML II mice have a total loss of acid hydrolase
phosphorylation, which results in depletion of acid hydrolases in mesenchymal-derived cells. The ML III c mice retain partial
phosphorylation. However, in both cases, total brain extracts have normal or near normal activity of many acid hydrolases
reflecting mannose 6-phosphate-independent lysosomal targeting pathways. While behavioral deficits occur in both
models, the onset of these changes occurs sooner and the severity is greater in the ML II mice. The ML II mice undergo
progressive neurodegeneration with neuronal loss, astrocytosis, microgliosis and Purkinje cell depletion which was evident
at 4 months whereas ML III c mice have only mild to moderate astrocytosis and microgliosis at 12 months. Both models
accumulate the ganglioside GM2, but only ML II mice accumulate fucosylated glycans. We conclude that in spite of active
mannose 6-phosphate-independent targeting pathways in the brain, there are cell types that require at least partial
phosphorylation function to avoid lysosomal dysfunction and the associated neurodegeneration and behavioral
impairments.
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Introduction
Mucolipidosis II (ML II) and mucolipidosis III (ML III) are
autosomal recessive lysosomal storage diseases caused by a
deficiency of UDP-GlcNAc:lysosomal enzyme N-acetylglucosa-
mine-1-phosphotransferase (GlcNAc-1-phosphotransferase), an
a2b2c2 hexameric enzyme that catalyzes the first step in the
synthesis of the mannose 6-phosphate (Man-6-P) targeting signal
on lysosomal hydrolases which is required for their targeting to
lysosomes in many cell types [1]. GlcNAc-1-phosphotransferase is
encoded by two genes, GNPTAB and GNPTG, which give rise to
the a/b subunit precursor and the c subunit, respectively. The a/
b subunits contain the catalytic function of the enzyme, whereas
the c subunit enhances the phosphorylation of a subset of
lysosomal hydrolases [2]. In humans, mutations in GNPTAB give
rise to ML II (MIM# 252500) or ML III a/b (MIM# 252600),
whereas mutations in GNPTG cause ML III c (MIM# 252605)
[3]. Patients with the rapidly progressive and severe ML II exhibit
a total or near total loss of GlcNAc-1-phosphotransferase activity
mostly due to nonsense or frameshift mutations while ML III a/b
patients tend to have missense or splice-site mutations resulting in
some residual GlcNAc-1-phosphotransferase activity and a milder
clinical course [4]. Patients with ML III c retain the most
phosphorylation activity of the three disorders and have the
mildest course. In fibroblasts and other mesenchymal cells of the
patients, lysosomal acid hydrolases which lack the Man-6-P
recognition marker are not properly sorted to the lysosome but
rather secreted into the patient’s blood stream. The resultant low
intracellular levels of these acid hydrolases lead to lysosomal
dysfunction and accumulation of undegraded material. However,
it has been shown that some non-mesenchymal cells have the
ability to traffic lysosomal hydrolases to lysosomes via Man-6-P-
independent mechanisms [5]. Thus, the level of some lysosomal
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hydrolases has been reported to be normal or near normal in total
brain, liver and muscle of ML II patients [6,7]. In spite of this,
these patients exhibit substantial neurologic manifestations includ-
ing early cessation of neuromotor development, limited verbal
expression, and moderate intellectual disability [4]. To better
understand the consequences of complete and partial loss of the
Man-6-P-targeting signal on neurologic function and brain
pathology, we performed neurological characterization of ML II
(Gnptab2/2) and ML III c (Gnptg2/2) mouse models [8,9]. ML II
mice have a total loss of acid hydrolase phosphorylation whereas
ML III c mice have a variable decrease in hydrolase phosphor-
ylation [2,10]. Nevertheless, in both cases, the activity of multiple
acid hydrolases in brain extracts are normal or only moderately
decreased [10,11], as previously reported for human patients [6,7].
Here we report the results of these studies and compare the
neurologic abnormalities we found with those reported by
Kollmann et al. [12] in a different mouse model of ML II.
Materials and Methods
Mice
All mice were housed in a barrier facility at 24uC on a fixed 12-
hour light and 12-hour dark cycle and were fed rodent chow
#5001 (Purina, St. Louis, MO) ad libitum. All protocols involving
the use of animals were in compliance with the National Institutes
of Health’s Guide for the Care and Use of Laboratory Animals
and approved by the Animal Studies Committee in the Division of
Comparative Medicine at Washington University School of
Medicine in St. Louis (Protocol #20130010). Mice were housed
in a barrier facility maintained under standards meeting federal,
state and local guidelines and under the supervision of licensed
veterinarians. We have previously reported the generation and
initial characterization of the Gnptab2/2 [8] and Gnptg2/2 mice
[10]. The Gnptab2/2 and Gnptg2/2 mice are maintained in a
C57Bl/6-129S5/SvEvBrd background. Mice were genotyped as
previously described to identify WT or knockout mice for use in
this study [8,10].
Behavioral Testing
Based on preliminary behavioral observations, Gnptab2/2 and
Gnptg2/2 mice were evaluated on a 1h locomotor activity test, a
battery of sensorimotor measures and the rotarod test (in that
order) to assess possible age-related impairments in motor/
sensorimotor functions. In the cohort of Gnptab2/2 mice and
their WT littermate controls, the sensorimotor battery was
conducted 1 day after the activity test with the rotarod test being
conducted 1 day after the sensorimotor battery when the mice
were evaluated at 1 month of age. The same was true for the
testing conducted at 4–5 months of age except that the 1h activity
test was not conducted at this age. The same sequence of tests was
used for the cohort of Gnptg2/2 and their strain and age-matched
WT control mice although the times intervening between tests
were different as were the ages at testing (4–6 and 12–14 months).
In this latter cohort, the sensorimotor battery was conducted
within 48 h of the activity test and the rotarod test was conducted
12–14 days after the activity test.
1h locomotor activity and sensorimotor battery
Locomotor activity was evaluated in the mice using transparent
(47.6 6 25.4 6 20.6 Cm high) polystyrene enclosures and
computerized photobeam instrumentation as previously described
[13]]. General activity variables (total ambulations, vertical
rearings) along with indices of emotionality including time spent,
distance traveled and entries made in a 336 11 cm central zone
were analyzed. All mice were also evaluated on a battery of
sensorimotor tests designed to assess balance (ledge and platform),
strength (inverted screen), coordination (pole and inclined screens)
and initiation of movement (walking initiation), as previously
described [13,14].
Rotarod
Motor coordination and balance were further studied using
procedures similar to our previously published methods [14,15].
Our rotarod protocol included three conditions: a stationary rod; a
rod that rotated at a constant speed (2.5 rpm for 60 s maximum);
and a rod that rotated at an accelerating speed (2.5 – 10.5 rpm
over 1–180 s maximum). The protocol consisted of three training
sessions with each session including one stationary rod trial, two
constant speed rotarod trials, and two accelerating speed rotarod
trials. Sessions were separated by 4 days to minimize motor
learning and time spent on the rod was used as the dependent
variable to assess performance. Note that one mouse from the
Gnptab2/2 group was deleted from the data set because it
appeared to have difficulty moving one of its forepaws and another
mouse was deleted from the WT control group because it climbed
over different parts of the apparatus making it impossible to record
valid times on the rod.
Statistical analyses for behavioral data
Analysis of variance (ANOVA) models were used to analyze the
behavioral data. Repeated measures (rm) ANOVA models
containing two between-subjects variables (Genotype and Sex)
and one within-subjects (repeated measures) variable (i.e., Time
Blocks) were used to analyze the ambulatory activity and vertical
rearing data. A similar model was used to analyze the rotarod data
although two within-subjects variables (i.e., trials and sessions)
were included to analyze the constant speed and accelerating
rotarod data. Typically, one-way ANOVA models were used to
analyze differences between groups for the other activity variables
and measures in the sensorimotor battery. The Huynh-Feldt
adjustment of a levels was utilized for all within-subjects effects
containing more than two levels to protect against violations of
sphericity/compound symmetry assumptions underlying rmA-
NOVA models. Pairwise comparisons were conducted following
relevant, significant overall ANOVA effects, which were subjected
to Bonferroni correction when appropriate, although planned
comparisons were also conducted.
Immunohistochemistry
Mice of the indicated ages were anesthetized and perfused
through the heart with 10% neutral buffered formalin (Sigma, St.
Louis, MO) and fixed for 4 days in 10% neutral buffered formalin
(Sigma, St. Louis, MO) at RT. The brain and spinal cords of
perfused mice were left in place within the skull and vertebral
columns, respectively, and post-fixed by immersion in 10%
buffered Formalin for at least 24 h before being decalcified in
formic acid (TBD-2 Decalcifier; ThermoFisher Scientific, Wal-
tham, MA). Coronal sections of brain and spinal cord were
embedded in paraffin, sectioned at 4 mm, mounted on positively
charged glass slides (Superfrost Plus; Thermo Fisher Scientific,
Waltham, MA), and dried in a 60uC oven for 20 min. Antigen
retrieval on tissue sections was completed in a pressure cooker
(Decloaking Chamber; Biocare Medical, Concord, CA) in citrate
buffer, pH 6 for 15 min at 110uC, followed by incubation with the
primary antibodies. The primary antibodies used in this study
included: anti-Iba1 (ionizing calcium-binding adaptor molecule 1:
CP290A; BioCare Medical) diluted to 1:250 and applied for 2 h at
RT; anti-GFAP (glial fibrillary acidic protein: Z0334; Dako,
Neurologic Abnormalities in ML II and ML III
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Carpinteria, CA), diluted to 1:1500 and applied for 1 h at RT;
anti-LAMP-1 (lysosomal-associated membrane protein 1 ab24170;
Abcam, Cambridge, MA), diluted 1:400 and applied for 1 h at
RT; anti-LC3B (microtubule-associated protein 1 light chain-3B:
I7543, Sigma, St. Louis, MO), diluted 1:2000 and applied for 2 h
at RT; anti-MAC2 (macrophage cell-surface protein 2: ACL-
8942AP, Accurate, Westbury, NY) diluted 1:20,000 and applied
for 30 min at RT; anti-NFP (M0762; Dako) diluted 1:40 and
applied for 2 hours at RT; and anti-ubiquitin (Z0458, Dako)
diluted 1:800 and applied for 15 min at RT. Binding of primary
antibodies (GFAP, IBA1, LAMP-1, LC3B) was visualized using
rabbit or rodent polymeric horseradish peroxidase method
(BioCare Medical, Concord, CA) on a LabVision stainer (Thermo
Fisher Scientific, Freemont, CA). Binding of MAC2 and NFP was
visualized using streptavidin horseradish peroxidase (Thermo
Fisher), with 3,39-diaminobenzidine as the chromogenic substrate
and a light hematoxylin counterstain. Binding of primary antibody
for ubiquitin was visualized using Bond Polymer Refine Red
Detection Kit (Leica, Bannockburn, IL).
Lipid Analysis
Mice of ages indicated were anesthetized and perfused through
the heart with PBS, brain tissues isolated and frozen at -80uC until
used. Sample preparation and quantification of sphingolipid
species by tandem mass spectrometry (LC-MS/MS) was per-
formed as previously described [16].
Determination of amino sugars content
Mice of ages indicated were anesthetized and perfused through
the heart with PBS, brain tissues isolated and frozen at 280uC
until used. Whole brains were homogenized in water, sonicated
and an aliquot was saved to determine the protein concentration.
The remaining lysate was brought to 4N Hcl (Sigma, St. Louis,
MO), heated in a sand bath at 100uC for 4 h, lyophilized, re-
suspended in 1mL water, and insoluble material spun down at
25,000Xg for 10 min. The supernatant was isolated and stored at
220uC. Amino sugar content was determined by the Reissig assay
[17] with known concentrations of N-Acetylglucosamine (Sigma,
St. Louis, MO) used as a standard. Each sample was normalized to
protein concentration and data plotted as nmol amino sugars/mg
total protein.
Determination of fucose content
Mice of ages indicated were anesthetized and perfused through
the heart with PBS, brain tissues isolated and frozen at 280uC
until used. Whole brains were homogenized in water, sonicated
and an aliquot saved for protein concentration. The remaining
lysate was adjusted to pH 1.0 with 1M H2SO4 (Sigma, St. Louis,
MO), heated in a sand bath at 100uC for two h, neutralized with
barium hydroxide (Sigma, St. Louis, MO), and the volume
adjusted to 1 mL with water. After 30 min at 4uC, samples were
spun down at 25,000Xg for 10 min and the supernatant isolated
and stored at 220uC. Fucose content was determined by the
Dische assay [18] with known concentrations of fucose (Sigma, St.
Louis, MO) used as a standard. Each sample was normalized to
protein concentration and the data plotted as nmol fucose/mg
total protein.
Fucosidase activity assay
Mice were anesthetized and perfused through the heart with
PBS, brain tissues isolated and frozen at 280uC until used. Whole
brains were homogenized in PBS containing 1% Triton-X (Sigma,
St. Louis, MO) and protease inhibitors (complete mini protease
inhibitor tablets; Roche, Penzberg, Germany), placed on ice for
15 min, sonicated and centrifuged for 10 min at 25,000Xg. An
aliquot of the supernatant was reserved for protein determination
and fucosidase activity of the supernatant was determined by
fluorometic enzyme assay as previously described [10]. Activity
was expressed as nmoles of hydrolyzed methylumbelliferone per
mg protein per h.
Results
Behavioral Analyses in Gnptab2/2 and Gnptg2/2 mice
Before starting the behavioral tests to investigate the impact of
complete or partial acid hydrolase Man-6-P deficiency on motor
and sensorimotor functions, we noted that the Gnptab2/2 mice,
but not the Gnptg2/2 mice, developed a hind limb clasping
response between 4–6 months of age, suggestive of brain and/or
spinal cord abnormalities [19]. In view of this, we initiated the
behavioral testing at 1 month of age in the Gnptab2/2 mice to
determine whether more subtle motor/sensorimotor impairments
were present during the juvenile period long before the clasping
response became apparent during early adulthood. The same
cohort of Gnptab2/2 mice was retested at 4–5 months to assess the
progression of functional impairment. We also focused on tests
that did not rely heavily on visual function since the Gnptab2/2
mice have progressive retinal degeneration starting at 2–3 months
with complete photoreceptor degeneration by 10 months [8]. The
Gnptg2/2 mice were assessed on these same tests as young adults
(4–6 months) and in middle age (12–14 months).
Gnptab2/2 mice exhibit sensorimotor deficits that
progress with age
At one month of age, results from the 1h locomotor activity test
showed that the Gnptab2/2 mice performed similarly to WT
control mice in terms of general ambulatory activity, vertical
rearing frequency, distance traveled in the periphery, and
measures of emotionality including distance traveled, time spent,
and entries made into a central zone in the test field (data not
shown). In contrast, the Gnptab2/2 mice exhibited impairment on
3/7 measures within the battery of sensorimotor tests. Specifically,
significant genotype effects derived from ANOVAs conducted on
these data revealed the following performance deficits in the
Gnptab2/2 mice: 1) Gnptab2/2 mice remained on the elevated
platform for a significantly shorter period of time (Fig. 1A)
compared to the WT control mice (p = 0.026); 2) the Gnptab2/2
mice took significantly longer to climb down the pole (Fig. 1B)
relative to WT mice (p = 0.0007); and 3) the Gnptab2/2 mice
were able to remain upside down on the inverted screen for
significantly less time (Fig. 1C) versus the WT controls (p =
0.020; See Table S1 for all F statistics associated with these
significant effects). No significant effects involving genotype were
found for the ledge (Fig. 1D), walking initiation, or 60u and 90u
inclined screen tests (data not shown). When tested on the
sensorimotor battery at 4–5 months of age, a similar pattern of
results was found, although the performance deficits of the
Gnptab2/2 mice were generally worse at this later age, typically
resulting in larger differences between the groups (Fig. 1E–H).
Besides a significant genotype effect, a significant sex effect (p =
0.025) and genotype x sex interaction (p = 0.041) were also
revealed by the ANOVA conducted on the ledge data (Table
S1). Subsequent contrasts showed that the male Gnptab2/2 mice
were significantly impaired on the ledge test compared to the
male WT mice (p = 0.002), while differences were not
significant between the females of each group (Fig. 2A). No
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significant main or interaction effects involving sex were found
for any of the other sensorimotor measures.
The Gnptab2/2 mice also showed mildly impaired performance
on some components of the rotarod test at 1 month of age
(Fig. 1I–K). A repeated measures ANOVA (rmANOVA) revealed
significant genotype (p = 0.002) and sex (p = 0.026) effects along
with a significant genotype by trials interaction (p = 0.0004) for
the stationary rod condition (Fig. 1I; Table S1). Subsequent pair-
wise comparisons showed that the Gnptab2/2 mice spent
significantly less time on the stationary rod compared to WT
control mice during trial 1 (p = 0.0007; Table S1). The Gnptab2/2
mice were also significantly impaired relative to the WT control
mice on the constant speed rotorod, but a significantly genotype x
sessions interaction (p= 0.024) showed that this depended on the
test session, with the greatest differences found during session 1
(Fig. 1J). No significant effects involving genotype were found for
the accelerating rotarod data at 1 month of age. The performance of
the Gnptab2/2 mice declined with age such that robust (and
significant) differences were found relative to the WT group for
every trial across test sessions for each component of the rotarod
procedure (Fig. 1L–N; Table S1) when the mice were retested at 4–
5 months of age.
Gnptg2/2 mice have mild-to-moderate sensorimotor
deficits
Analyses of the data from the 1h locomotor activity test of
Gnptg2/2 mice and the corresponding WT control group carried
out at 4–6 months of age showed that the two groups performed
similarly in terms of general ambulatory activity (Fig. 3A), vertical
rearing (Fig. 3B), distance traveled in the periphery, and with
regard to the emotionality (center) variables (not shown). The two
groups also did not differ in several components of the
sensorimotor battery, including walking initiation and the ledge,
pole, and inverted screen tests (not shown). However, the Gnptg2/2
mice exhibited significant performance deficits on the 60u and 90u
inclined screen tests (Fig. 3C–D) compared to the WT mice
(genotype effects: p = 0.0005 and 0.0001, respectively; Table S2).
The ANOVA conducted on the 60u inclined screen data also
yielded a significant genotype x sex interaction, (p = 0.041), with
impaired performance being found for the male Gnptg2/2 mice
compared to the males from the WT group (p = 0.0003), while the
performance of the females from the two groups did not differ
significantly (Fig. 2B). The Gnptg2/2 group also tended to perform
poorly on the platform test relative to the WT control mice, but
these differences were not significant at this age (Fig. 3E). The data
from the 1h locomotor activity test conducted when the mice were
12–14 months of age showed that the ambulatory activity and
vertical rearing frequency of the Gnptg2/2 mice were generally
reduced relative to theWT littermates during the initial stages of the
test (Fig. 3F–G;
Table S2). In addition, the Gnptg2/2 group exhibited decreased
vertical rearing frequency compared to the WT control mice
(Fig. 3G; p = 0.043; Table S2), with differences between the
groups being greatest during block 1 (p = 0.049). Similar to the
activity results from the earlier age, no differences were observed
between groups with regard to distance traveled in the periphery,
or the emotionality variables (not shown). Although the Gnptg2/2
mice showed a strong trend towards inferior performance at 12–14
months compared to WT littermate control mice with regard to
the 60u inclined screen test, the differences were not significant like
they were at the earlier time point (Fig. 3H). However theGnptg2/2
mice again showed a significant performance deficit relative to the
WT group on the 90u inclined screen and also that the older mutant
mice were impaired on the platform test (Fig. 3I–J; p = 0.026 and
0.010, respectively; Table S2). Again, no group differences were
observed on the walking initiation, ledge, platform or pole tests at
the 12–14 month testing (not shown).
The Gnptg2/2 mice also exhibited impaired performance on
the rotarod test that was conducted when the mice were 4–6
months of age. They performed poorly during the first trial of the
stationary rod component compared to the littermate WT group,
but then the two groups performed comparably for the next two
trials (Fig. 3K; Table S3). Additional contrasts showed that it was
the female Gnptg2/2 mice, not the males, who accounted for the
impaired performance on trial 1 (Fig. 2C, Table S3). Gnptg2/2
mice exhibited greater performance impairments on the constant
speed rotarod (Fig. 3L) where they spent significantly less time on
the rotarod on average across the trials and sessions (p = 0.005;
Table S3). The impaired performance of the Gnptg2/2 mice was
greatest during the accelerating rotarod test (Fig. 3M) where an
rmANOVA yielded a significant genotype effect (p = 0.0003) and
significant genotype x sessions (p = 0.002) and genotype x sex x
trials (Fig. 2D; p = 0.004) interaction (Table S3). When the mice
were retested on the rotarod at 12–14 months of age, no
performance differences were observed on the stationary rod
(Fig. 3N) although large deficits were again observed on the part of
the Gnptg2/2 mice for the constant speed and accelerating rotarod
components (Fig. 3O–P;Table S3).). The rmANOVA on these
data also yielded a significant genotype x sex x trials x sessions
interaction (p = 0.017). Additional contrasts revealed that the
female Gnptg2/2 mice were significantly impaired on average
across trials and sessions relative to the WT females (Fig. 2E; p =
0.0001). Performance deficits were also observed in the male
Gnptg2/2 mice versus the male WT controls on average across
trials and sessions, although the effect was smaller compared to
that of the female groups (Fig. 2E; p = 0.022).
Figure 1. Gnptab2/2 mice exhibit performance deficits on sensorimotor and rotarod tests which show progressive impairment with
age. (A–D) At 1-month of age, the Gnptab2/2 mice spent significantly (*p= 0.026) less time on an elevated platform (A), took significantly (*p =
0.0007) longer to climb down a pole (B), and spent significantly (*p = 0.020) less time hanging upside down on an inverted screen (C) compared to
WT littermate control mice. The Gnptab2/2 mice also showed a nonsignificant trend in terms of spending less time on an elevated ledge (D). (E-H)
Larger performance deficits were observed when the mice were tested at 4-5 months of age when significant impairment was observed in the
Gnptab2/2 group compared to WT controls on the platform (E; *p = 0.0002), pole (F; *p = 0.0005), inverted screen (G; *p,0.00005), and ledge (H; *p
= 0.001) tests (see Fig. 3A for details of sex effects on the ledge test). (I-K) The Gnptab2/2 mice demonstrated mild performance impairments on the
rotarod when they were tested at 1-month of age. (I) For example, the Gnptab2/2 mice spent significantly less time on the stationary rod component
of the test compared to the WT group (genotype effect, {{p = 0.002); genotype x trials interaction (**p = 0.0004), but this was mostly due to
differences observed on trial 1 (*p = 0.0007). (J) Analysis of the constant speed rotarod data showed that large differences were observed between
the Gnptab2/2 and WT groups but only during the first session (genotype x sessions interaction; **p = 0.024); trial 1 ({p = 0.046); trial 2 (*p = 0.022).
(K) No significant effects involving Genotype were found as a result of analyzing the accelerating rotarod data. (L-M) The Gnptab2/2 mice showed
severely impaired performance on the rotarod tasks when tested at 4–5 months of age. Specifically, the Gnptab2/2 mice were significantly impaired
on the stationary rod (L; genotype effect: **p ,0.00005; pairwise comparisons for each trial: *p ,0.0005), the constant speed rotarod (M; genotype
effect: **p ,0.00005; pairwise comparisons for each trial: *p ,0.003), and accelerating rotarod (N; genotype effect: ***p ,0.00005; genotype x trials
interaction: **p ,0.010; pairwise comparisons for each trial: *p ,0.003).
doi:10.1371/journal.pone.0109768.g001
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Figure 2. Sex effects on behavior in Gnptab2/2 and Gnptg2/2 mice. (A) In addition to a significant genotype effect, an ANOVA conducted on
the ledge data from the Gnptab2/2 and WT control mice at 1 month of age revealed a significant sex effect (p = 0.025) and a genotype x sex
interaction (p = 0.041). Subsequent contrasts showed that male Gnptab2/2 mice were significantly impaired on the ledge test compared to the male
WT mice [F(1,23) = 12.98, *p = 0.002], while differences were not significant between the female groups. (B) Analysis of the 60u inclined screen data
from the 4-6 month old Gnptg2/2 mice showed a significant genotype x sex interaction (p = 0.041) in addition to the significant genotype effect,
suggesting that impaired performance may have varied differentially as a function of sex in each group. Additional contrasts documented that the
male Gnptg2/2 mice took significantly longer to reach the top of the apparatus compared to the males from the WT group [F(1,16) = 21.51, *p =
0.0003), while the performance of the females from the two groups did not differ significantly. (C) An rmANOVA on the stationary rod data from
testing the Gnptg2/2 and control mice at 4–6 months of age revealed a significant sex x trials interaction, (**p = 0.030) as well as a significant (*)
genotype effect and a significant (***) genotype x trials interaction, suggesting that differences in performance were dependent on trials and sex.
Additional contrasts showed that the performance of the male groups of mice did not differ across the stationary rod trials, although the female
Neurologic Abnormalities in ML II and ML III
PLOS ONE | www.plosone.org 6 October 2014 | Volume 9 | Issue 10 | e109768
Histopathology
We initially used routine hematoxylin and eosin (H&E) stained
sections of brain and spinal cord from WT, Gnptab2/2 and
Gnptg2/2 mice to evaluate these tissues and then added periodic
acid-Schiff (PAS) and immunohistochemistry (IHC) staining
methods to more fully characterize the CNS lesions. Tissues were
obtained from WT and Gnptab2/2 mice at 4, 6, 10 and 12 months
of age and from 12-month-old Gnptg2/2 mice. At 4 months, no
notable changes were seen in the CNS of WT or Gnptab2/2 mice
by routine H&E staining, but by 6 months of age, Gnptab2/2 mice
showed widely dispersed swollen dystrophic axons and neurites in
multiple foci within the brain, the afferent spinal nerves and the
dorsal horn grey matter of the spinal cord. The severity of clinical
signs and the extent of associated histopathological lesions in
Gnptab2/2 mice continued to increase over time. In the 10- and
12-month-old Gnptab2/2 mice dystrophic axons/neurites and
spheroids were widely dispersed in the brainstem and dorsal grey
matter of the spinal cord. These changes were particularly severe
in the medial piriform (olfactory) cortex (Fig. 4A–B), especially in
the area tempestas and along the midline from the lateral septal
nucleus through the medial septal nucleus to the optic chiasm. In
the spinal cord, dystrophic axons were mainly located within the
dorsal nerve root, dorsolateral fasciculus, and dorsal root entry
zone, whereas dystrophic neurites were concentrated in the
superficial laminae of the dorsal horn grey matter (Fig. 4C–D).
In both ascending and descending white tracts of the spinal cord
there was diffuse vacuolization and rarefaction, with occasional
axonal spheroids in 10- and 12-month-old Gnptab2/2 mice. In
addition, 10- and 12-month-old Gnptab2/2 mice showed multi-
focal depletion of Purkinje cells in the cerebellum (Fig. 4E–F).
Staining for GFAP in cerebellum of 6-month old Gnptab2/2 mice
showed bilaterally symmetrical parasagittal bands of activated
Bergmann glial cells that coincided precisely with zones of
Purkinje cell loss (Fig. 4G–H).
In marked contrast to the widespread pathological findings
observed in Gnptab2/2 mice, Gnptg2/2 mice which do not display
any abnormal clasping behavior did not develop any of the swollen
dystrophic axons/neurites or white tract lesions that were
widespread in the brains and spinal cords of age-matched
Gnptab2/2 mice. In fact, no CNS lesions of any type were
detected in Gnptg2/2 mice when using only H&E stained sections
of the brain and spinal cord. However, as shown later, special
staining methods used to study the tissues in more detail did reveal
mild multifocal lesions in Gnptg2/2 mice, but these were much
more extensive in Gnptab2/2 mice.
CNS tissues of 12-month-old Gnptab2/2 mice stained by the
PAS method revealed widely dispersed PAS positive granular
staining in macrophages and microglia throughout most areas of
brain and spinal cord (Fig. 5B). Most of the strongly PAS-positive
material was clearly cytoplasmic and restricted to microglia and
macrophages. These changes were not present in the CNS of age-
matched WT controls and were rare in Gnptg2/2 mice (Fig. 5A/
C). Genotype related differences in PAS staining were particularly
evident within the white tracts and molecular layers of the
cerebellum (compare Fig. 5E to 5D/F). These panels also show
the selective loss of Purkinje cells in the Gnptab2/2 tissue. Some of
the larger neurons in both brain and spinal cord of the 12-month-
old WT mice contained perinuclear clusters of very small and
sharply defined PAS-positive granules, which likely represent
lipofuscin (Fig. 5G). However, age-matched Gnptab2/2 mice had
markedly increased amounts of larger and paler-staining granular
material in the perinuclear cytoplasm of numerous large and
medium size neurons (Fig. 5H). Although similar pale-pink
granular material was seen in some neurons of Gnptg2/2 mice,
it was present in smaller amounts and in far fewer neurons than in
age-matched Gnptab2/2 mice (Fig. 5I).
CNS tissues from the various types of mice were stained for
ionized-calcium binding protein (Iba1), ubiquitin (UBQ), and glial
fibrillary acidic protein (GFAP) in order to detect microglia,
ubiquinated proteins, and astrocytes respectively. These staining
methods served to highlight the true extent and progression of
lesions in Gnptab2/2 and Gnptg2/2 mice. For example, staining
for Iba1 showed no evidence of increased labeling in 12-month-old
WT mice (Fig. 6A) but some Iba1-positive reactive microglia were
detectable in the CNS of 4-month-old Gnptab2/2 mice and by 6
months Iba1 staining of Gnptab2/2 CNS showed diffuse moderate
activation of microglia throughout the brain and spinal cord
(Fig. 6B). The extent and severity of reactive microgliosis
continued to increase in 12-month-old Gnptab2/2 mice (Fig. 6C).
In contrast to the widespread inflammatory and degenerative
changes detected by IHC staining methods in 12-month-old
Gnptg2/2 mice, we found that CNS lesions in age-matched
Gnptg2/2 mice were extremely limited in extent and severity.
Only mild reactive microgliosis was present in 12-month-old
Gnptg2/2 mice (Fig. 6D). Similarly, ubiquitin-positive granules
were rarely detected in the white tracts of 12-month-old WT mice
(Fig. 6E) but the amount and extent of ubiquitin-positive granules
in Gnptg2/2 mice increased in severity between ages 6 and 12
months (Fig. 6F, 6G). Although granular ubiquitin inclusions were
abundant in the older Gnptg2/2 mice in white tracts (especially
with the corpus callosum and cerebellum) and dorsal sensory grey
matter of the spinal cord, there was no significant labeling of either
reactive microglia or neurons for ubiquitin. In contrast, there was
only a minimal increase in ubiquitin staining in 12-month-old
Gnptg2/2 mice (Fig. 6H). The GFAP staining showed increased
reactive astrogliosis present throughout the brain and spinal cord
Gnptg2/2 mice were significantly impaired compared to the WT controls, [F(1,16) = 6.72, p = 0.020), with significant differences being observed on
the first trial ({{p = 0.004). (D) Robust performance impairments in the Gnptg2/2 mice at 4-6 months of age were observed during the accelerating
rotarod test where an rmANOVA yielded a significant genotype x sex x trials interaction, (***p = 0.004), along with a significant (*) genotype effect
and significant (**) genotype x sessions interaction. Subsequent contrasts relating to the sex effect showed that the male Gnptg2/2mice remained on
the rod longer than the male control group [F(1,16) = 5.64, p = 0.031) with significant differences occurring on session 3 - trial 1 ({p = 0.002),
although large differences were also found for session 1 - trial 2 (#p = 0.036) and session 2 - trial 1 (#p = 0.039). Differences were even greater in
the female groups whereby the female Gnptg2/2 mice performed significantly worse than the control females [F(1,16) = 17.65, p = 0.0007), with
significant differences being observed for session 1 - trial 2 ({{p = 0.0007), session 2 - trial 2 ({{p = 0.0004), session 3 - trial 1 ({{p = 0.0002), and
session 3 - trial 2 ({{p = 0.002). (E) Analysis of the accelerating rotarod data at 12–14 months revealed a significant genotype x gender x trials x
sessions interaction, (**p = 0.017), as well as a significant (*) genotype effect. Additional contrasts related to the sex variable showed that the female
Gnptg2/2 mice exhibited significantly inferior performance on average across trials and sessions compared to the female WT group [F(1,15) = 25.37,
p = 0.0001). Pair-wise comparisons revealed significant differences between the female groups on every trial ({{p ,0.007) except session 1 - trial 1
(##p = 0.016), where differences were also very large. The performance of the male Gnptg2/2 mice was also significantly compromised relative to
the male WT controls on average across trials and sessions, although the differences were smaller [F(1,15) = 6.48, p = 0.022). Pair-wise comparisons
showed that the performance of the male groups differed significantly on session 2 - trial 2 ({p = 0.006), although large differences were also
observed on session 1 - trial 2 (#p = 0.049), and session 3 - trial 2 (#p = 0.041).
doi:10.1371/journal.pone.0109768.g002
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of the 6- and 12-month-old Gnptg2/2 mice, with the progression
of this lesion most clearly demonstrated in the molecular layer of
the cerebellum. Whereas IHC staining for GFAP in this area
showed only faint staining of Bergmann glial cells in WT mice
(Fig. 6I), by 6 months of age Gnptg2/2 mice showed bilaterally
symmetrical parasagittal bands of activated Bergmann glial cells
that coincided precisely with zones of Purkinje cell loss (Fig. 4G,
6J). The Purkinje cell loss and associated thinning of the molecular
layer as well as the activation of associated Bergmann glia were
much more prominent in 10- and 12-month-old Gnptg2/2 mice
(Fig. 6K). Except for some small areas of mild reactive astrogliosis
in the cerebellar peduncles and white tracts, no notable changes in
GFAP staining patterns were seen in the brain or spinal cord of 12-
month-old Gnptg2/2 mice (Fig. 6L). Another indicator of the
progressively increased severity of CNS inflammation in Gnptg2/2
mice was demonstrated by the appearance of galectin-3 (MAC2: a
marker for inflammation) staining in the white tracts in both brain
and spinal cord. WT mice were essentially negative for galectin-3
staining (Fig. 6M) but cerebellar white tracts, trigeminal nerves,
and dorsal/dorsolateral white tracts of the spinal cord in 6-month-
old Gnptg2/2 mice were labeled for this marker (Fig. 6N). The
extent and severity of labeling increased in proportion to the
amount of nerve damage and by 12 months of age Gnptg2/2 mice
showed diffuse staining of cerebellar peduncles and white tracts in
the cerebellum (Fig. 6O) and widespread staining of ventrolateral
fasciculi in the spinal cord. The much milder MAC2 reactivity in
12-month-old Gnptg2/2 mice was also primarily found in the
white tracts and peduncles of the cerebellum (Fig. 6P) although
small foci were also labeled in spinal cord white tracts.
In addition to the increased labeling by Iba1 and MAC2 of cells
found in almost all areas of the brain and spinal cord of Gnptg2/2
mice, there was enhanced LAMP-1 (Lysosomal-associated mem-
brane protein 1) staining in these areas, indicative of lysosomes
distended by undigested material. The LAMP-1 labeling that is
evident in many neurons of the Gnptg2/2 mice (Fig. 7E) was also
mildly increased in Gnptg2/2 mice in comparison to WT controls
(Fig. 7F vs. 7D). In the molecular layer of the cerebellum in WT
mice, Iba1 labels non-reactive resident microglia (Fig. 7A) but no
MAC2 staining is evident (Fig. 6A). However, in Gnptg2/2 mice
there are numerous enlarged Iba1/MAC2 positive macrophages
(Fig. 6O, 7B) in the molecular areas showing loss of Purkinje cells.
Only mild activation of microglia is evident in the molecular layer
in 12-month-old Gnptg2/2 mice (Fig. 7C).
Of note, the LAMP-1 staining in WT cerebellum is limited
primarily to the Purkinje cell layer (Fig. 7D). In contrast, LAMP-1
labeling in Gnptg2/2 mice is prominent in the enlarged
macrophages/microglia in the molecular layer but is reduced in
the areas of Purkinje cell loss (Fig. 7E). Although Purkinje cell loss
and hypertrophy of phagocytic cells are not seen in the molecular
layer of 12-month-old Gnptg2/2 mice, there is an increased
amount of LAMP-1 staining in the Purkinje cell and molecular
layers (Fig. 7F), suggesting that there is a subclinical increase in
lysosomal storage in these areas. The markedly increased extent of
LAMP-1 staining of perinuclear cytoplasmic granules in neurons
in Gnptg2/2mice indicates greater lysosomal storage in neurons in
comparison to WT and Gnptg2/2 mice.
Similar differences in LAMP-1 staining were noted in the spinal
cord white tracts in WT, Gnptg2/2 and Gnptg2/2 mice. In all
mice, LAMP-1 was detected within oligodendrocytes, identified
based on morphology, location in white tracts and lack of staining
for MAC2 and Iba1. However, the extent of labeling was
markedly increased in Gnptg2/2 mice due to the more extensive
cytoplasmic volume and extensions of reactive microglia and
hypertrophic oligodendrocytes (Figs. 7G,H,I). It was also noted
that endothelial cells in WT mice were LAMP-1 negative but that
the microvesiculated endothelium of meningeal veins (not arteries)
in Gnptg2/2 and Gnptg2/2 mice was LAMP-1 positive although
markedly more so in the Gnptg2/2 mice (Figs. 7J,K,L).
Finally, we used PAS staining and selected IHC stains to better
characterize the nature/origin of the swollen dystrophic axons/
neurites, which were seen only in the brain and spinal cord of the
Gnptg2/2 mice. Notably, the numerous dystrophic axons and
neurites in 10-12-month-old Gnptg2/2 mice were consistently
negative for PAS (Fig. 8A). The staining of the dystrophic axons/
Figure 3. Gnptg2/2 mice show mild to moderate performance deficits on activity, sensorimotor and rotarod tests. (A-B) Although the
Gnptg2/2 mice tended to show lower levels of ambulatory activity (A) and vertical rearing frequency (B) relative to WT littermate controls on the 1-h
locomotor activity test when tested at 4–6 months of age, no significant effects involving genotype were found following analyses conducted on
these data. However the Gnptg2/2 group took significantly longer to climb to the top of the 60u (C) and 90u (D) inclined screens, (genotype effects:
*p = 0.0005 and 0.0001, respectively), and showed a nonsignificant trend toward being able to remain on the platform for a shorter time compared
to WT control mice (E) when tested at this age (see Fig. 3B for details of sex effects on the 60u inclined screen). (F) When the 1-h activity test was
conducted at 12–14 months of age, the Gnptg2/2 mice tended to be less active compared to controls, although this depended on the time block of
the test session (genotype x time interaction: *p = 0.012), with the largest group differences being observed during the first time block ({p = 0.041).
(G) At this age, the Gnptg2/2 group also showed significantly reduced rearing frequency on average across time blocks, (genotype effect: *p = 0.043),
with the largest differences occurring during the first block ({p = 0.049). (H) During testing at 12-14 months of age, the performance level of the
Gnptg2/2 mice tended to be much lower than that of the WT control group on the 60u inclined screen, but the differences were not statistically
significant. However, the Gnptg2/2 mice did show significant performance deficits at this age on the 90u inclined screen (I) and platform tests (J),
(genotype effects: *p = 0.026 and *p = 0.010, respectively). The Gnptg2/2 strain was also impaired on the rotarod when tested at 4–6 months of age.
(K) For example, a significant genotype effect (*p = 0.024) indicated that the Gnptg2/2 mice were impaired on the stationary rod component of the
rotarod although this effect was mostly due to differences observed during trial 1 ({{p = 0.007), whereas their performance on the other two trials
were similar to those of the WT group (see Fig. 3C for details of sex effects). (L) The Gnptg2/2 group also exhibited significant performance
impairments on the constant speed rotarod on average across trials and sessions (genotype effect: *p = 0.005), with group differences being
significant for session 1 - trial 2 (**p = 0.004), while large differences were also observed for session 2 - trial 2 ({p = 0.044) and session 3 - trial1 ({{p
= 0.019). (M) Analysis of the accelerating rotarod data also revealed significant performance deficits on the part of the Gnptg2/2 mice (genotype
effect: **p = 0.0003; genotype x sessions interaction: *p = 0.002), although this was somewhat dependent on the sessions variable. Pair-wise
comparisons showed that group performances differed significantly for session 1 - trial 2, session 2 - trial 2, and session 3 - trial 1 (***p,0.0009), while
large differences were observed for session 2 - trial 1 ({p = 0.012) and session 3 - trial 2 ({{p = 0.009). (See Fig. 3D for details concerning sex effects.)
When the mice were re-tested at 12-14 months, the groups were found to perform similarly on the stationary rod (N). However, the Gnptg2/2 group
again showed significant deficits on the constant speed rotarod (O) which was documented by a significant genotype effect (**p = 0.0003). Pair-wise
comparisons showed that the Gnptg2/2 mice had significantly reduced times on the rod for session 1 - trial 2 (***p = 0.0003) and session 2 - trial 2
(*p = 0.004), with large differences also being found for session 2 - trial1 ({p = 0.033). (P) The Gnptg2/2 group was also significantly impaired again
on the accelerating rotarod when re-tested at the later age, (genotype effect: **p = 0.0001) when pair-wise comparisons showed significant group
differences across all trials and sessions (*p ,0.008; ***p ,0.0005) (see Fig. 3E for details of sex effects).
doi:10.1371/journal.pone.0109768.g003
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neurites for the other markers was highly variable. For example,
there was widespread granular staining of most dystrophic axons/
neurites for ubiquitin (Fig. 8B) while IHC staining for the
autophagy marker LC3B (Fig. 8C) and the lysosome/late endo-
some marker LAMP-1 (Fig. 8D) showed variable (negative to mild)
staining. In contrast, strong staining for neurofilament protein
(NFP) was present in only a few dystrophic axons in the white
tracts of the cerebellum and spinal cord of Gnptg2/2 mice while
the abundant large swollen neurites in the superficial laminae
(layers 1 to 3) of the dorsal horn grey matter were consistently
NFP-negative (Fig. 8E) with only a few bodies scattered in deeper
laminae (layers 4-9) being NFP-positive. Taken together, these
staining results were indeterminate, but suggest that the bodies in
the swollen dystrophic axons/neurites may consist of a mixture of
distended autophagosomes and autolysosomes.
Analysis of CNS storage material
The findings of PAS positive material in the CNS of 10- and 12-
month-old Gnptg2/2 mice indicated the presence of carbohydrate-
containing storage material. To better characterize the nature of
the carbohydrate accumulation found in the CNS of Gnptg2/2
mice, we determined the content of total amino sugars and fucose
in the brains of the mutant mice. These assays showed a small
accumulation of amino sugars in the CNS of 12-month-old
Gnptg2/2 mice that did not reach statistical significance (Fig. 9A)
but a significant increase in the level of fucose (p,0.05) (Fig. 9B).
In contrast, the level of these sugars was normal in the Gnptg2/2
mice. Assay of whole brain extracts of WT or mutant mice for
lysosomal a-L-fucosidase activity showed that the Gnptg2/2 mice
had a decreased level of this hydrolase that did not quite achieve
significance (p = 0.0587) whereas the Gnptg2/2 mice had a
significant decrease in a-L-fucosidase activity (p = 0.0059)
(Fig. 9C). One explanation for the lack of correlation between
fucose accumulation and reduction in a-L-fucosidase activity is
that these changes are not uniform among the various cell types in
the brain and the assays of total brain tissue obscures changes in
specific cell types.
Mass Spectrometry analysis of brain tissue from 12-month-old
Gnptg2/2 mice revealed an accumulation of GM2 in the
cerebrum and brainstem while Gnptg2/2 mice had accumulation
of GM2 in the cerebrum, cerebellum and brainstem (Fig. 10). No
significant changes were found in the level of GM3 and the level of
GM1 showed a decrease in cerebrum and brainstem for the
Gnptg2/2 mice. The Gnptg2/2 mice also had an accumulation of
ceramide in all three regions of the brain and a reduction in
dihexosylceramides in the brainstem and cerebellum. These data
suggest that in some cells of the brain, the activites of a-L-
fucosidase, b-hexosaminidase and likely other acid hydrolases are
sufficiently deficient to allow the accumulation of undigested
material in lysosomes.
Figure 4. Histological lesions in H&E stained sections of brain and spinal cord were detected only in Gnptab2/2 mice. (A) Swollen
dystrophic axons/neurites in piriform cortex of 12-month-old Gnptab2/2mice, but absent in WT controls (B). (C) Axonal spheroids were present in the
afferent nerves (thick arrow) and dystrophic neurites (thin arrows) were concentrated in the superficial laminae of the dorsal horn grey matter of the
spinal cord of Gnptab2/2 mice, but were entirely absent in the spinal cords of WT controls (D). (E) Cerebellum of 10/12-month-old Gnptab2/2 mice
with Purkinje cell loss (arrow) not seen in the Purkinje cell layer (arrow) in WT controls (F). (G) Staining for GFAP in cerebellum of 6-month old
Gnptab2/2 mice showing bilaterally symmetrical parasagittal bands (arrows) of activated Bergmann glial cells that coincided precisely with zones of
Purkinje cell loss. (H) Negative GFAP staining of Bergmann’s glia was evident in WT mice. (Figures A-F 40X, Bar = 100 mm; Figures G and H; 4X, Bar =
1 mm)
doi:10.1371/journal.pone.0109768.g004
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Discussion
In this study we used mouse models of ML II and ML III c to
compare and contrast the course of neurologic and behavioral
changes associated with either complete or partial loss of the Man-
6-P-targeting signal. We previously reported that both Gnptg2/2
and Gnptg2/2 mice had unremarkable neurologic exams up to 14
weeks with the exception of increased pain tolerance in the
Gnptg2/2 mice [9]. However, we subsequently observed that the
Gnptg2/2 mice developed a hind limb clasping response between
4-6 months. This prompted us to initiate more extensive
behavioral and pathologic studies of the two mouse models. We
found that the Gnptg2/2 mice start exhibiting performance deficits
on behavioral tests that assess sensorimotor functioning at 1 month
of age, with progressive deterioration in performance being
observed at 4 months. Results from the rotarod and pole tests
suggest that the Gnptg2/2 mice have impaired coordination
between the forelimbs and the hindlimbs, although compromised
strength and balance (inverted screen and platform test results)
may contribute to this. Although differences in the experimental
designs of the Gnptg2/2 and Gnptg2/2 studies make it inappro-
priate to directly compare the results between the two models, it
appears that the Gnptg2/2 mice generally showed less severe
sensorimotor deficits suggesting more mildly disrupted sensorimo-
tor functions than the Gnptg2/2 strain and possibly less extensive
neuropathology.
The more extreme behavioral disturbances in the Gnptg2/2
mice were associated with progressive neurodegeneration charac-
terized by microgliosis, astrocytosis, Purkinje cell loss, widely
dispersed swollen dystrophic axons and neurites filled with
granular material along with the accumulation of PAS- and
ubiquitin-positive granules in various cell types. The changes were
widespread, involving the spinal cord, brainstem, cerebrum and
cerebellum. The dystrophic neurites and axons in the spinal cord
of Gnptg2/2 mice were concentrated in the dorsal horn and
extended into the dorsal columns, suggesting that sensory neurons
and pathways were affected. Lesions in the ventral and lateral
regions of the spinal cord primarily involved the white tracts and
were characterized by vacuolization of axons and hypertrophy of
associated LC3B-positive oligodendrocytes. Some motor neurons
contained increased amounts of PAS-positive material (lipofus-
cin?). Taken together, these findings suggest that subsets of both
sensory and motor neurons were affected in Gnptg2/2 mice, in
contrast to the almost normal histopathology of the Gnptg2/2
mice.
The hypertrophy and increased LAMP-1 staining of oligoden-
drocytes in areas of white tract vacuolization suggests that
oligodendrocytes are particularly susceptible to the lysosomal
enzyme deficiencies that occur in Gnptg2/2 mice. Lesions
involving both white tracts and neurons were widespread but
not diffuse in both the brain and spinal cord, indicating that cell
subsets in the CNS differ in their susceptibility to lysosomal
enzyme deficiencies. Similar lesions were not present in gamma
KO mice.
The immunohistochemical staining for GFAP in the Gnptg2/2
cerebellum showed a striking pattern with the cellular processes of
reactive Bergmann glial cells appearing as prominent parasagittal
bands. Notably, these bands of reactive GFAP-positive Bergmann
glia correlated directly with areas of Purkinje cell degeneration and
loss, a pattern also seen in the brains of humans and mice with
Figure 5. CNS tissue stained by the Periodic acid-Schiff method. (A) The CNS of 12-month-old WT mice lacked PAS-positive macrophages
and microglia. (100X; Bar = 20 mm) (B) 12-month-old Gnptab2/2 mice exhibited widely dispersed enlarged PAS-positive microglia/macrophages
(thin arrows) throughout most areas of brain and spinal cord. (C) PAS-positive microglia in Gnptg2/2 mice were rare and small (thin arrow). (D) PAS-
positive cells were absent in the white tracts and molecular layers of the WT cerebellum, abundant (thin arrows) in Gnptab2/2 cerebellum (E), and
absent in Gnptg2/2 cerebellum (F). (G) Some of the larger neurons in brain and spinal cord of 12-month-old WT mice contained perinuclear clusters of
very small, sharply defined PAS-positive granules. Age-matched Gnptab2/2 mice (H), had markedly increased amounts of paler-staining granular
material in the perinuclear cytoplasm of numerous large and medium size neurons (thick arrow) in addition to enlarged microglia/macrophages (thin
arrows). The Gnptg2/2 mice had low numbers of the pale-pink granular cytoplasmic material (thick arrows) (I).
doi:10.1371/journal.pone.0109768.g005
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Figure 6. Cerebellar staining for ionized-calcium binding protein 1 (Iba1), ubiquitin (UBQ), glial fibrillary acidic protein (GFAP), and
galectin-3 (MAC2) to detect microglia, ubiquinated proteins, astrocytes, and inflammation respectively. (A-D), IHC staining for Iba1
showed small microglia with delicate cytoplasmic extensions in 12 month old WT tissue (A), diffuse reactive microgliosis In 6-month-old Gnptab2/2
mice (B), markedly increased staining in 12-month-old Gnptab2/2 mice (C), and only mild activation of microglia in 12-month-old Gnptg2/2 mice (D).
(E) Ubiquitin-positive granules were rarely detected in cerebellar white tracts of 12-month-old WT mice. (F,G) The amount and extent of ubiquitin-
positive granules increased in severity between 6 and 12 months of age in Gnptab2/2 mice. (H) There was a minimal increase in ubiquitin staining in
12-month-old Gnptg2/2 mice. (I-L) IHC staining for GFAP showed faint staining of Bergmann glial cells in 12-month-old WT mice (I), mild multifocal
activation of Bergmann glial cells in 6 month old Gnptab2/2 mice (J), bilaterally symmetrical areas of Purkinje cell loss with associated thinning of the
molecular layer and diffuse activation of Bergmann glia in 12-month-old Gnptab2/2 mice (K) and no notable change in GFAP staining patterns
involving Bergmann glia in 12-month-old Gnptg2/2 mice (L). (M-P) IHC staining of galectin-3 (MAC2) was negative in the CNS tissues of WT mice (M),
but showed progressive staining of cerebellar peduncles and white tracts of 6 and 12 month old Gnptab2/2mice (N,O). MAC2 reactivity was mild and
mostly restricted to the white tracts and peduncles of the cerebellum in 12 month old Gnptg2/2 mice (P). Figures A - H and M - P, 20X; Bar =
100 mm); Figures I - L, 40X; Bar = 100 mm).
doi:10.1371/journal.pone.0109768.g006
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Figure 7. CNS staining for ionized-calcium binding protein 1 (Iba1) and lysosomal-associated membrane protein1 (LAMP-1). IHC
staining of the cerebellum for Iba1 (A-C) and LAMP-1 (D-F). (A) Molecular layer of cerebellum in 12-month-old WT mice showing nonreactive resident
microglia characterized by fine cytoplasmic extensions. (B) In 12-month-old Gnptab2/2 mice, there are numerous enlarged Iba1/MAC2 positive
macrophages in the molecular layers associated with Purkinje cell loss. (C) In 12-month-old Gnptg2/2mice, there was only mild activation of microglia
in the molecular layer. (D) LAMP-1 in 12-month-old WT cerebellum is limited primarily to the Purkinje cell layer. (E) In contrast, LAMP-1 labeling in 12-
month-old Gnptab2/2 mice is prominent in the enlarged macrophages/microglia in the molecular layer but reduced in the areas of Purkinje cell loss.
(F) There was a slightly increased amount of LAMP-1 staining in the Purkinje cell and molecular layers of 12-month-old Gnptg2/2 mice, suggesting a
subclinical increase in lysosomal storage in these areas. In (G-I) similar genotype-related differences in LAMP-1 staining are shown in spinal cord white
tracts in 12-month-old WT, Gnptab2/2 and Gnptg2/2 mice, respectively. In all genotypes LAMP-1 was detected within oligodendrocytes, but the
extent of labeling was markedly increased in Gnptab2/2 mice (H) due to increased volume of cytoplasm and extensions of hypertrophic
oligodendrocytes, as well as reactive microglia and macrophages. (I) In 12-month-old Gnptg2/2 mice, LAMP-1-positive oligodendrocytes are also
larger and more prominent than in WT mice, but microglia/macrophages are uncommon. (J-L) Endothelial cells in meningeal veins in WT mice were
consistently LAMP-1 negative (J), but microvesiculated endothelium of meningeal veins (not arteries) in both Gnptab2/2 (K) and Gnptg2/2 (L) mice
was LAMP-1 positive, although markedly more so in the Gnptab2/2 mice. (Figs. A - I at 40X,Bar = 100 mm; Figs. J - L at 60X, Bar = 50 mm)
doi:10.1371/journal.pone.0109768.g007
Figure 8. PAS and IHC staining of brain and spinal cord dystrophic axons and neurites of 12-month-old Gnptab2/2 mice. (A) The
dystrophic axons and neurites were consistently negative for PAS (arrows). (B) There was widespread granular staining of most dystrophic axons/
neurites for ubiquitin (arrows). In contrast, IHC staining for the autophagy marker LC3B (C) and the lysosome/endosome marker LAMP-1 (D) showed
variable (negative to mild) staining of dystrophic axons/neurites (arrows). (E) Strong staining for neurofilament protein (NFP) was present in only a few
dystrophic axons in the white tracts of the cerebellum and spinal cord of Gnptab2/2mice, while the abundant large swollen neurites in the superficial
laminae (layers 1 to 3) of the dorsal horn grey matter were consistently NFP-negative (arrows). (40X; Bar = 100 mm)
doi:10.1371/journal.pone.0109768.g008
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other lysosomal storage disorders, such as Juvenile neuronal ceroid
lipofuscinosis [20]. The cerebellum is organized into genetically
defined subdivisions that appear to form distinct functional units
within the cerebellum [21-23]. Many other markers have shown
similar staining patterns of parasagittal bands in normal cerebel-
lum and the bands appear to correlate with different Purkinje cell
subtypes having well-established patterns of gene expression
[22,24].
It is difficult to compare these findings to those reported for ML
II patients since only a few autopsies have been reported and most
of them did not include IHC stains. However, for both ML II
patients and mice, macroscopic evaluation of the brain and spinal
cord revealed little to no abnormalities, but the microscopic
examination reported here showed evidence of storage material,
vacuolization, Purkinje cell loss and positive PAS staining in
neurons.
In contrast to the Gnptg2/2 mice, the Gnptg2/2 mice showed
impaired performance on only a few of the behavioral tests and
these abnormalities did not become evident until these mice were
much older compared to Gnptg2/2 mice (4-6 months versus 1
month), although more precise information regarding the age of
onset of these behavioral deficits requires testing at earlier ages in
the Gnptg2/2 mice. Further, changes in the Gnptg2/2 mouse
brain were slower to develop and much milder in extent and
severity than those seen in the Gnptg2/2 mice. This correlates well
with the finding that ML III c patients have normal to mildly
impaired neurologic functioning [25-27]. In the present study, we
have also described a few genotype-dependent sex effects in the
two strains of mutant mice. Presently, the significance of these
findings for the two forms of mucolipidoses being modeled here is
not clear, yet we have mentioned them to promote further
research into possible sex effects in the human disorders.
It is interesting that in spite of finding that the activity of a
number of acid hydrolases in total brain extracts of the Gnptab2/2
and Gnptg2/2 mice is normal or only moderately decreased and
even increased in a few instances [10,11], several types of storage
materials were detected in the brains of the mutant mice,
especially in the Gnptab2/2 mice, consistent with defective
lysosomal function. PAS positive material and increased fucose-
containing glycans were found in the brains of older Gnptab2/2
mice but not Gnptg2/2 mice whereas both types of mutant mice
showed accumulation of GM2 in their cerebrum and brainstem.
However, it must be noted that secondary accumulation of GM2
has been reported in a number of lysosomal storage diseases [28].
Gnptab2/2 mice also had an accumulation of ceramide in all three
regions of the brain. Since accumulation of gangliosides has been
associated with inflammation and neuronal degeneration [28], this
abnormality could potentially be a contributing factor in the
neurologic abnormalities present in the Gnptab2/2 and Gnptg2/2
mice. However, it seems unlikely that this ganglioside accumula-
tion is the predominant factor in the development of the CNS
pathology and behavioral alterations seen in the Gnptab2/2 mice
as GM2 accumulates to similar levels in the Gnptab2/2 mice and
the more mildly affected Gnptg2/2 mice. Since we did not analyze
individual subpopulations of cells in the brain, we cannot exclude
the possibility that the GM2 accumulation is happening in
different cells types or regions of the brain in the two models
thus influencing the degree or type of impairment. However, a
more likely explanation is the accumulation of different materials
or different amounts of undigested material in the CNS of
Gnptab2/2 mice versus the Gnptg2/2 mice.
While this work was in progress, Kollmann et al. [12] reported
neurologic findings in a mouse model of ML II generated by
knocking in a version of Gnptab containing a mutation originally
identified in ML II patients, Gnptabc.3028insC [29]. In many
respects the findings with the two models are similar although
there are some differences. One concerns life span. The vast
majority of our Gnptab2/2 mice survive to 40 weeks and then
either die or have to be euthanized due to disease progression by
60 weeks (data not shown). In contrast, the Gnptabc.3082insC mice
have a steady decline in survival starting at birth with,50% of the
mice dead prior to 40 weeks and only a few surviving up to 64
weeks [12]. Importantly, both models exhibit many similar
neurologic abnormalities including prominent astrogliosis, activat-
ed microglia, swollen axons containing storage material in the
cerebellum along with the loss of Purkinje cells. However, we do
not find the reduction in cerebellar size reported in the
Gnptabc.3082insC mice. This abnormality has also not been
reported in ML II patient autopsies. The Gnptabc.3082insC mice
also showed an accumulation of cholesterol in the Purkinje and
granule layer of the cerebellum based on filipin staining [12]
whereas we did not detect cholesterol accumulation by MS in
either the Gnptab2/2 or Gnptg2/2 mice. This difference may be
due to the methods used to detect cholesterol since filipin staining
can detect alterations in the subcellular distribution of cholesterol
that don’t necessarily involve an increase in the total content of this
compound. Finally, we have previously reported that the levels of
LC3-II, LAMP-2 and ubiquitinated proteins in the brains of
Gnptab2/2 mice were unchanged as determined by western
blotting [11]. This differs from the finding in the brain of
Gnptabc.3082insC mice, which showed increased LC3-II and p62
using this technique. However, using IHC we did detect increased
staining of ubiquitin-positive granules in white tracts, especially in
the corpus callosum and cerebellum, and the dorsal sensory gray
matter of the spinal cord at 6 months of age with considerable
progression at 12 months of age.
Figure 9. Gnptab2/2 mice have an accumulation of fucosylated oligosaccharides in the brain. One-year-old WT, Gnptab2/2 or Gnptg2/2
mice were perfused with PBS and CNS material harvested and frozen until analyzed. Levels of amino sugars (A), or fucosylated glycans was
determined (B) (data plotted as mean 6SD, n = 3-5, *P,0.05). (C) Six months – 1 year old WT, Gnptab2/2 or Gnptg2/2 mice were perfused with PBS
and whole brain lysates were used to determine the activity of a-L-fucosidase (data plotted as mean 6SD, n = 6-10. All data was analyzed using an
unpaired Student’s t-test.
doi:10.1371/journal.pone.0109768.g009
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Figure 10. Analysis of Gangliosides and other lipids in Gnptab2/2 and Gnptg2/2 mice brains. Cerebrum, cerebellum or brain stem was
isolated from 12-month-old WT, Gnptab2/2 or Gnptg2/2 mice and the isolated lipids analyzed by mass spectrometry. Each sample was analyzed in
duplicate and normalized to protein content (ng species/mg total protein) with n= 6 mice for WT and n= 3 for Gnptab2/2 and Gnptg2/2 mice. Ratio
of lipid species/mg protein for WT mice was set to 1 (mean 6 SD, *p,0.05). Data shown represents the d18:1, C18:0 species for GM1, GM2 and GM3.
The dihexosylceramide, monohexosylceramide, ceramide data represents the d18:1, C16:0 species. All data was analyzed using an unpaired Student’s
t-test.
doi:10.1371/journal.pone.0109768.g010
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The modest differences in the two models may be a result of
several factors. One possibility is that since the Gnptab2/2 mice
were generated through an insertional mutagenesis strategy [8],
some degree of splicing may occur around the gene-trap cassette,
resulting in the generation of a small amount of GlcNAc-1-
phosphotransferase that might be sufficient to target low levels of
acid hydrolases to the lysosome. We previously reported that the
acid hydrolases of the brain of Gnptab2/2 mice had no detectable
Man-6-P phosphorylation (less than 2% in these assays) whereas
the same acid hydrolases of WT mice had 41-82% phosphoryla-
tion [2,10]. Other possibilities behind the difference include mixed
strain differences (Gnptab2/2 mice in C57BL/6-129SvEvBrd
versus Gnptabc.3082insC mice in C57BL/6-129SvJ) or secondary
effects of residual C-terminally truncated a/b precursor protein in
the Gnptabc.3082insC mice such as activation of the endoplasmic-
reticulum-associated protein degradation (ERAD) system. Regard-
less of these differences in the two mouse models of ML II, the
finding that both exhibit severe neurodegeneration confirms that
the Man-6-P independent sorting pathway is unable to fully
support adequate lysosomal function in the CNS. The more
benign course of the Gnptg2/2 mice shows that the partial
phosphorylation of acid hydrolases is effective in decreasing the
lysosomal dysfunction and lessening the associated neurodegener-
ation and behavioral changes.
Addendum
While this manuscript was in revision, Paton et. al., (Paton L,
Bitoun E, Kenyon J, Periestma DA, Oliver PL et. al., (2014) A
novel mouse model of a patient mucolipidosis II mutation
recapitulates disease pathology. The Journal of biological chem-
istry, in press. Published on August 8, 2014) reported a new mouse
model of ML II, characterized by growth retardation, skeletal and
facial abnormalities and reduced life span. These mice exhibited
impaired motor function and psychomotor retardation. Histolog-
ical analysis showed progressive degeneration in the cerebellum.
While many of the features are similar to those found in our
mutant mice, our mice lack the craniofacial defects found in the
new model and the very early onset of death.
Supporting Information
Table S1 Note that one Gnptab2/2 mouse that had an injured
paw and one WT mouse that continually climbed onto the
apparatus rather than remaining on the rod were dropped from
the analyses of the rotarod data.
(PDF)
Table S2 Note that one WT mouse died between the 4–6
months old and 12–14 months old tests. Abbreviation: Incl. =
Inclined
(PDF)
Table S3 Significant ANOVA effects involving genotype (Geno)
and sex variables from the rotarod test in 4–6 and 12–14 months
old Gnptg2/2 and WT mice.
(PDF)
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